Lumos Diagnostics Holdings (ASX:LDX) Total Premiums Earned

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LDX Lumos Diagnostics Holdings Ltd ASX:LDX
26 GF Score
Price A$0.12
GF Value A$0.03
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Lumos Diagnostics Holdings Total Premiums Earned?

Total Premiums Earned only applies to insurance companies.

ASX:LDX
26GF Score
Lumos Diagnostics Holdings Ltd ASX:LDX
Total Premiums Earned is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?

Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued. The current stock price of A$0.12 is trading 300% above its estimated GF Value™ of A$0.03. GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.

Key valuation signals for ASX:LDX:

  • Total Premiums Earned:
  • GF Value™: A$0.03 vs. price of A$0.12 (300% above fair value)
  • GF Score™: 26/100 with 2 warning signs

No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDXHF:USA
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is an Australian point-of-care diagnostics company, though the United States is its primary market. Its flagship product is FebriDx, a rapid fingerstick blood test that helps clinicians distinguish between viral and bacterial respiratory infections by measuring two host immune response biomarkers, myxovirus resistance protein A and C-reactive protein. The company also provides contract research and development services, offering assay development, manufacturing, and commercialization support for third parties developing point-of-care diagnostic tests. Customers include hospitals, emergency departments, urgent care clinics, physician offices, and diagnostic companies seeking development partners. Lumos operates as a single business segment spanning diagnostics products and services, generating revenue through product sales of FebriDx and related tests plus fee-for-service contract development work. The company is headquartered in Australia and maintains operations in the United States, where most of its revenue is earned.
26GF Score

Get the complete analysis for ASX:LDX

Total Premiums Earned is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price
A$0.03
GF Value